This has already started to take place, as the stock has moved lower by 25.2% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for IPCI stock.
If that wasn’t enough, IntelliPharmaCeutics isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.
Consider that in the last 30 days, 1 estimate has been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.
That is why we currently have a Zacks Rank #4 (Strong Sell) on this stock and are looking for it to underperform in the weeks ahead. So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for IPCI.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
INTELLIPHARMACEUTICS INTERNATION (IPCI): Free Stock Analysis Report
Zacks Investment Research